Amiodarone interaction with β-blockers: Analysis of the merged EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) databases

Circulation

Volumn 99, Issue 17, 1999, Pages 2268-2275

  Boutitie, Florent ^a   Boissel, Jean Pierre ^a,h   Connolly, Stuart J ^b   Camm, A John ^d   Cairns, John A ^b   Julian, Desmond G ^e   Gent, Michael ^b   Janse, Michiel J ^f   Dorian, Paul ^c   Frangin, Gerald ^g  

^a UNIVERSITÉ LYON 1   (France)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^e Netherhall Gardens   (United Kingdom)

^f ACADEMIC MEDICAL CENTER   (Netherlands)

^g SANOFI   (France)

^h Service de Pharmacologie Clinique   (France)

Author keywords

Antiarrhythmia agents; Myocardial infarction; Trials

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HEART ARRHYTHMIA; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0032900853     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.99.17.2268     Document Type: Article

References (12)

1. Amiodarone Trials Meta-analysis Investigators. The effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual patient data on 6500 patients from randomized trials. Lancet. 1997;350:1417-1424.
2. Kodama I, Kamiya K, Toyama J. Cellular electropharmacology of amiodarone. Cardiovasc Res. 1997;35:13-29.
3. Charlier R. Cardiac actions in the dog of a new antagonist of adrenergic excitation which does not produce competitive blockade of adrenoceptors. Br J Pharmacol. 1970;39:668-674.
4. Tonet J, Frank R, Fontaine G, Grosgogeat Y. Efficacy and safety of low doses of beta-blocker agents combined with amiodarone in refractory ventricular tachycardia. PACE. 1988;11:1984-1989.
5. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet. 1997;349:667-674.
6. Cairns JA, Connolly SJ, Roberts, R, Gent M, for the Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Lancet. 1997; 349:675-682.
7. Boissel JP, Peyrieux JC, and the EPSIM Research Group Sub-grouping of post myocardial infarction patients according to their 1-year death risk. Eur Heart J. 1987;8:1272-1280.
8. Janse MJ, Malik M, Camm AJ, Julian DG, Frangin G, Schwartz PJ. Identification of post-MI patients with potential benefit from treatment with amiodarone, a sub-study of EMIAT. Eur Heart J. 1998;19:85-95.
9. Hodeige D, Heyndrickx J-P, Chatelain P, Manning A. SR 33590, a new amiodarone-like antiarrhythmic agent: anti-adrenoceptor activity in anesthetized and conscious dogs. Eur J Pharmacol. 1995;279:25-32.
10. Perret G, Yin Y-L, Nicolas P, Pussard E, Vassy R, Uzzan B, Berdeaux A. amiodarone decreases cardiac β-adrenoceptors through an antagonistic effect on 3′, 5, 3′ triiodothyronine. J Cardiovasc Pharmacol. 1992;19: 473-478.
11. Chatelain P, Meysman L, Mattéazi JR, Beaufort PH, Clinet M. Interaction of the antiarrhythmic agents SR 33589 and amiodarone with the β-adrenoceptor and adenylate cyclase in rat heart. Br J Pharmacol. 1995;116:1949-1956.
12. Kadish AH, Chen R-F, Schmaltz S, Morady F. Magnitude and time course of beta-adrenergic antagonism during oral amiodarone therapy. J Am Coll Cardiol. 1990;16:1240-1245.